A Phase 2, Two-Arm, Double-Blind, Multi-Center, Randomized Study of the Combination of Oral WX-671 [Wilex] Plus Capecitabine [Xeloda; Hoffman La Roche AG] vs. Capecitabine Monotherapy in First-Line Her2-Negative Metastatic Breast Cancer.

Trial Profile

A Phase 2, Two-Arm, Double-Blind, Multi-Center, Randomized Study of the Combination of Oral WX-671 [Wilex] Plus Capecitabine [Xeloda; Hoffman La Roche AG] vs. Capecitabine Monotherapy in First-Line Her2-Negative Metastatic Breast Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Oct 2017

At a glance

  • Drugs Upamostat (Primary) ; Capecitabine
  • Indications Advanced breast cancer
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Heidelberg Pharma AG; WILEX AG
  • Most Recent Events

    • 19 Oct 2017 According to a Heidelberg Pharma AG media release, WILEX AG changed its name to Heidelberg Pharma AG.
    • 04 Jun 2013 Results presented at the 49th Annual Meeting of the American Society of Clinical Oncology.
    • 11 Apr 2013 Results will be presented at the 2013 Annual Meeting of the American Society of Clinical Oncology (ASCO-2013) according to a WILEX media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top